• About ArQule
• Product R & D
• Clinical Trials
• Investors and Media
  • Press Releases
  • Events
  • Corporate Presentation
  • Recent Data Presentations
  • Corporate Governance
  • Financial Information
  • Stock Information
  • Contact Us
• Careers

Investors and Media

Our mission as a biotechnology company is to research, develop and commercialize a next-generation of small molecule cancer therapeutics. We are combining innovative, proprietary anti-cancer technology with world-class chemistry capabilities to generate drug candidates that target multiple tumor types, act selectively against cancer cells and are well tolerated by patients. Our lead products are in clinical development, and our research pipeline targets multiple molecules with established roles and therapeutic potential in cancer.

We are headquartered and operate research facilities and development programs in Woburn, Massachusetts.

 

Recent Releases

May 17, 2012
Positive Phase 2 Clinical Data with Tivantinib in Hepatocellular Carcinoma to Be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology

May 3, 2012
ArQule Reports First Quarter 2012 Financial Results

Recent Events

May 3, 2012 at 9:00 AM ET
Q1 2012 ArQule, Inc. Earnings Conference Call

Corporate Presentation

Apr 17, 2012

View Presentation  3.2 MB

Stock Chart	Stock Quote
3 Mo.   6 Mo.   1 Yr.	ArQule NASDAQ: ARQL Price: 6.20 Change: - 0.53 Day High: 6.80 Day Low: 6.12 Volume: 842,500 Delayed at least 20 minutes. Provided by eSignal.

Transfer Agent
American Stock and Transfer
41 Wall Street
New York City, NY 10005
Phone: 212-936-5100